AOD9604 vs Frag 176-191: Which Fat-Loss Peptide Is Right for You?
At a glance
- AOD9604 / A 15-amino-acid synthetic analogue of hGH residues 177-191 with an added N-terminal tyrosine (Tyr0), studied in human trials sponsored by Metabolic Pharmaceuticals in the 2000s
- Frag 176-191 / The unmodified 16-amino-acid C-terminal fragment of hGH (residues 176-191), studied mainly in rodent and cell-culture models
- Shared mechanism / Both are reported to act through beta-3 adrenergic receptor signaling on fat cells to promote lipolysis, without the hGH-receptor binding that drives IGF-1 production
- Regulatory status (as of 2025) / AOD9604 has an FDA GRAS designation for food-ingredient use; this is not drug approval. Frag 176-191 has no comparable FDA designation. Neither is FDA-approved to treat obesity or any disease
- Human evidence / AOD9604 has published oral human trial data; Frag 176-191's human clinical trial evidence is limited and specific figures require verification before being repeated to patients
The direct answer
AOD9604 and HGH Fragment 176-191 share a proposed mechanism and a similar dosing range in compounding practice, but they are not equivalent choices. AOD9604 is the peptide with an actual human trial record and a formal FDA safety designation (GRAS, food-ingredient context only), while Frag 176-191's supporting evidence is largely preclinical. If a patient and prescriber want to lean on the peptide with more human data, that is AOD9604. If the goal is exploring a mechanistically similar but less-studied alternative, that is Frag 176-191, and it should be understood as such rather than as an interchangeable substitute.
Neither peptide is FDA-approved to treat obesity, and neither has trial data showing weight loss anywhere near what GLP-1 receptor agonists (semaglutide, tirzepatide) produce in randomized trials. A qualified prescriber should confirm current regulatory status, sourcing, and personal risk factors before either peptide is used; this article does not provide individualized dosing advice.
What these peptides actually are
Human growth hormone (hGH, somatropin) is a 191-amino-acid protein. Researchers identified the C-terminal region of the molecule as carrying a fat-metabolizing effect that is largely separable from hGH's growth-promoting, IGF-1-raising activity. HGH Fragment 176-191 is that unmodified C-terminal segment. AOD9604 (the name stands for Anti-Obesity Drug 9604) is a stabilized derivative of that same fragment, produced by adding a tyrosine at what researchers call position 0.
Both peptides are reported, based on laboratory and animal studies, to activate beta-3 adrenergic receptors on adipocytes, triggering cAMP signaling and hormone-sensitive lipase activity that breaks down stored triglycerides. Because neither binds the hGH receptor with meaningful affinity, neither is expected to raise IGF-1 or blood glucose the way full-length recombinant hGH does. That mechanistic claim comes primarily from older rodent and in-vitro work; confirmatory human mechanistic studies are limited, and a prescriber relying on this distinction with a specific patient should verify it against current primary literature rather than assuming it applies uniformly.
AOD9604: what the human evidence supports, and where it stops
AOD9604 was developed by Metabolic Pharmaceuticals and taken through a multi-phase human clinical trial program, including a placebo-controlled trial in adults with elevated BMI, testing an oral formulation. Public and secondary reporting on that program describes a statistically detectable but modest placebo-adjusted weight effect over roughly 12 weeks of oral dosing. The exact trial size, dose, and effect size cited in older marketing and secondary sources vary, and a specific number should not be repeated to patients as established fact without verification against the original trial registration and any peer-reviewed publication of the results.
What is more solidly documented is regulatory: the FDA granted AOD9604 GRAS status for use as a food ingredient in 2014, a designation that speaks to an acceptable safety margin at studied doses but is explicitly not the same as approval to treat any medical condition. Subcutaneous AOD9604, at doses in the low hundreds of micrograms per day, is the route most often discussed in compounding and telehealth settings, but no completed large-scale human trial of that specific route and dose has been publicly confirmed. Animal studies going back to the late 1990s and 2000s reported reduced body fat with AOD9604 in obese rodent models without apparent effects on lean mass or blood glucose; translating rodent fat-loss magnitudes to expected human results is not appropriate, and no such extrapolation should be presented as a predicted human outcome.
HGH Fragment 176-191: mostly animal evidence
Frag 176-191 shares the proposed beta-3 adrenergic mechanism and the reported absence of IGF-1 stimulation, but the human evidence base behind it is thin. Its supporting data come predominantly from rodent and isolated-adipocyte studies showing lipolytic activity and, in some reports, reduced lipogenesis. As of this writing, no peer-reviewed, adequately powered randomized controlled trial of Frag 176-191 in humans has been confirmed in the literature available to this review. Doses used in compounding practice (commonly in the low hundreds of micrograms subcutaneously, once or twice daily) are extrapolated from animal pharmacokinetics rather than from human dose-ranging trials.
Frag 176-191 also lacks the FDA GRAS designation that AOD9604 holds. It exists in a less-defined regulatory space and, where prescribed, is generally compounded under a state-licensed 503A or 503B pharmacy arrangement rather than dispensed as an FDA-approved drug.
Evidence boundary: what is established, what is plausible, what is not
Established: Both peptides are C-terminal hGH-derived sequences studied for a proposed fat-metabolizing mechanism distinct from hGH's growth-promoting effects. AOD9604 has undergone human clinical testing and holds an FDA GRAS designation for food-ingredient use (2014). Neither peptide is FDA-approved to treat obesity, weight regain, or any other disease.
Plausible but not confirmed in humans at scale: That subcutaneous dosing produces meaningful, clinically significant fat loss in general adult populations; that Frag 176-191 performs comparably to AOD9604 in humans; that either peptide is a reasonable substitute for GLP-1 receptor agonist therapy in people seeking substantial weight loss.
Not established: Long-term safety data at compounded subcutaneous doses for either peptide; head-to-head human comparison of AOD9604 versus Frag 176-191; the specific magnitude of expected weight loss a given patient will experience with either compound.
Decision comparison: AOD9604 vs HGH Fragment 176-191
| Factor | AOD9604 | Frag 176-191 | Why it matters |
|---|---|---|---|
| Human clinical trial history | Yes, published oral-dose human trial program | No confirmed peer-reviewed human RCT | AOD9604 is the peptide with an actual human safety and efficacy record to point to, even if the effect size was modest |
| FDA designation | GRAS (food ingredient, 2014), not drug approval | None | GRAS at least establishes an FDA safety review at studied intake levels; Frag 176-191 has no equivalent record |
| Route with the most evidence | Oral, in the original trial program | None with human trial support | Common subcutaneous compounding use for either peptide is off the studied route |
| Mechanistic claim (no IGF-1/glucose rise) | Reported in animal and mechanistic studies | Reported in animal and mechanistic studies | Neither claim has been confirmed by a large modern human mechanistic trial; treat as plausible, not settled |
| Best-suited circumstance | A patient and prescriber who want the option with more human-trial history behind it, understanding the modest documented effect | A patient already familiar with AOD9604's evidence gaps who wants to discuss a mechanistically similar but less-studied alternative with their prescriber | Neither is a first-line obesity treatment; the choice is about evidence tolerance, not proven superiority |
| Regulatory sourcing | Can be found as a food-ingredient-grade material or, for injectable use, only through a compounding pharmacy under prescription | Compounding pharmacy under prescription only (503A/503B) | Injectable use of either peptide falls outside the FDA-approved-drug pathway |
Before starting either peptide, a prescriber should review fasting glucose or HbA1c, a lipid panel, and relevant metabolic history, and should discuss FDA-approved alternatives (including GLP-1 receptor agonists) for patients whose goal is substantial weight loss.
Related peptide comparisons readers ask about
These pairs come up alongside AOD9604 and Frag 176-191 in fat-loss and recovery-focused peptide discussions. Each is summarized briefly here; each deserves its own fuller evidence review before use.
BPC-157 vs TB-500. BPC-157 is a 15-amino-acid sequence derived from a gastric protective protein, studied mainly in animal models for tendon, ligament, and gut-lining healing, reportedly through angiogenesis promotion and local growth-factor signaling. TB-500 is a synthetic peptide based on the active region of thymosin beta-4, which binds actin monomers and is studied for systemic tissue repair and reduced inflammation, including in cardiac repair models. Neither has FDA approval, and no confirmed head-to-head human trial has compared them directly. In practice, BPC-157 is more often discussed for localized, injection-site healing, and TB-500 for broader systemic repair, but this distinction rests on mechanism and animal data rather than confirmed comparative human outcomes.
IGF-1 vs IGF-1 LR3. Native IGF-1 circulates largely bound to insulin-like growth factor binding proteins, which limits its free half-life to a short window while the bound complex extends effective circulation considerably. IGF-1 LR3 is a modified analogue engineered to bind these proteins far less, extending its active half-life substantially compared to native IGF-1. Mecasermin, a recombinant IGF-1 product, is FDA-approved (as Increlex) for severe primary IGF-1 deficiency in children; IGF-1 LR3 is not FDA-approved for any indication and its long-term safety, including any effect on cell proliferation signaling, has not been established in randomized human trials. Guideline bodies for growth hormone deficiency management generally recommend monitoring serum IGF-1 to avoid supraphysiologic levels; readers should consult current Endocrine Society guidance directly rather than a paraphrase, since exact wording should not be treated as an established quotation without verification.
Semax vs Selank. Both are peptides developed and studied primarily in Russia. Semax, an ACTH(4-7) analogue, is reported to raise BDNF signaling and has been studied for stroke recovery and cognitive effects; it is approved in Russia for some of these uses but has no FDA approval. Selank, a tuftsin analogue, is studied mainly for anxiolytic effects via GABA-A and enkephalin pathways, again without FDA approval. Specific trial sizes and outcome magnitudes reported for either peptide in secondary sources should be verified against the primary Russian-language or translated literature before being used to counsel a patient; this review does not have a verified primary citation for those figures.
GHRP-2 vs Ipamorelin. Both are ghrelin-receptor agonists that stimulate pulsatile growth hormone release. GHRP-2 is reported to meaningfully raise cortisol and prolactin as an off-target effect because ghrelin receptors are also present outside the growth-hormone axis; this makes it useful diagnostically (as a GH stimulation test under physician supervision) but generally less desirable for routine body-composition or sleep-focused use. Ipamorelin is reported to be more selective for the growth-hormone secretagogue receptor with less cortisol and prolactin co-stimulation, which is the main reason it is more commonly chosen over GHRP-2 in outpatient peptide protocols, often paired with a GHRH analogue such as CJC-1295 without DAC. Exact hormone-level figures from older trials should be verified against the primary paper before being quoted precisely.
When to involve urgent care instead
None of these peptides is appropriate for self-treating an acute injury, uncontrolled weight loss, signs of a growth-hormone-secreting tumor, or new neurological symptoms. Chest pain, sudden severe headache, vision changes, an injection site with spreading redness or fever, or any suspected allergic reaction after an injectable peptide warrants urgent medical evaluation rather than continued peptide use.
Frequently asked questions
Frequently asked questions
What is the difference between AOD9604 and HGH Fragment 176-191?
Does AOD9604 raise IGF-1 levels?
Is AOD9604 FDA-approved for weight loss?
Is Frag 176-191 legal to use in the United States?
Can either peptide replace a GLP-1 medication like semaglutide for weight loss?
What should be checked before starting a peptide like AOD9604?
A note on the evidence in this article
Several figures that circulate about these peptides online, including specific trial sizes, exact percentage weight-loss numbers, and precise hormone-level shifts, could not be verified against a confirmed primary source for this review. Where that was the case, this article describes the evidence qualitatively (for example, "a modest, statistically detectable effect") rather than restating an unverified number as fact. Anyone advising a patient with a specific figure from another source should trace it back to the original clinical trial registration or peer-reviewed publication before relying on it.
References
- U.S. Food and Drug Administration. GRAS Notice Inventory (food ingredient safety designations). https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory
- U.S. Food and Drug Administration. Drug approval and labeling information can be verified through FDA's Drugs@FDA database for products such as mecasermin (Increlex), which is FDA-approved for severe primary IGF-1 deficiency in children.
This article is for general education and has not yet completed qualified medical review. It does not provide individualized diagnosis, dosing, or treatment instructions. Discuss any peptide therapy, including risks, alternatives, and current regulatory status, with a licensed prescriber before use.